Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1) To compare the overall survival (OS) in subjects with PD-L1 strongly positive, 1L advanced/metastatic NSCLC treated with pembrolizumab compared to standard of care (SOC) chemotherapies. 2) To compare the OS in subjects with PD-L1 positive (strong and weak), 1L advanced/metastatic NSCLC treated with pembrolizumab compared to SOC chemotherapies.
Critère d'inclusion
- Non-Small Cell Lung Carcinoma